Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis

[1]  P. Ascierto,et al.  Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. , 2021, The Lancet. Oncology.

[2]  V. Sondak,et al.  Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Schneeweiss,et al.  LBA16 IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer , 2020, Annals of Oncology.

[4]  A. Schneeweiss,et al.  LBA15 Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC) , 2020 .

[5]  T. Akimoto,et al.  Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer , 2020, ESMO open.

[6]  R. McWilliams,et al.  Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients , 2020, Melanoma research.

[7]  Yonghao Yang,et al.  Chemotherapy Reverses Anti-PD-1 Resistance in One Patient With Advanced Non-small Lung Cell Cancer , 2020, Frontiers in Oncology.

[8]  Rui Xia,et al.  Metronomic paclitaxel improves the efficacy of PD-1 monoclonal antibodies in breast cancer by transforming the tumor immune microenvironment. , 2020, American journal of translational research.

[9]  R. Sullivan,et al.  Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy , 2018, Cancer.

[10]  E. Winer,et al.  Atezolizumab and Nab‐Paclitaxel in Advanced Triple‐Negative Breast Cancer , 2018, The New England journal of medicine.

[11]  N. Rizvi,et al.  Combining chemotherapy with PD‐1 blockade in NSCLC , 2018, Pharmacology & therapeutics.

[12]  P. Ascierto,et al.  Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma , 2017, The New England journal of medicine.

[13]  A. Hauschild,et al.  Adjuvant Dabrafenib plus Trametinib in Stage III BRAF‐Mutated Melanoma , 2017, The New England journal of medicine.

[14]  M. Zauderer,et al.  Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. , 2017, Immunotherapy.

[15]  S. Haferkamp,et al.  Can checkpoint inhibitor therapy improve response to chemotherapy , 2017 .

[16]  D. Schadendorf,et al.  Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. , 2017, The Lancet. Oncology.

[17]  J. Utikal,et al.  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. , 2017, European journal of cancer.

[18]  H. Soliman.  nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors , 2016, OncoTargets and therapy.

[19]  A. Hauschild,et al.  A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  P. Ascierto,et al.  Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. , 2015, The Lancet. Oncology.

[21]  H. Koon,et al.  What Is the Role of Chemotherapy in the Treatment of Melanoma? , 2014, Current Treatment Options in Oncology.

[22]  P. Darcy,et al.  Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment , 2013, Oncoimmunology.

[23]  K. Flaherty,et al.  Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  A. Santoro,et al.  Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Abastado.  The next challenge in cancer immunotherapy: controlling T-cell traffic to the tumor. , 2012, Cancer research.

[26]  C. Mackay,et al.  Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control. , 2011, Cancer research.

[27]  Y. Chu,et al.  CD4+Foxp3+ Regulatory T‐cell Impairment by Paclitaxel is Independent of Toll‐like Receptor 4 , 2011, Scandinavian journal of immunology.

[28]  Neil Desai,et al.  Randomized Crossover Pharmacokinetic Study of Solvent-Based Paclitaxel and nab-Paclitaxel , 2008, Clinical Cancer Research.

[29]  Patrick Soon-Shiong,et al.  Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. , 2006, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[31]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[32]  D. Schadendorf,et al.  Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.